<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7533207\results\search\country\results.xml">
  <result pre="East respiratory syndrome (MERS). A study from a hospital in" exact="Hong Kong" post="evaluated the efficacy of convalescent plasma therapy in the"/>
  <result pre="the time of plasma infusion. During the MERS epidemic in" exact="South Korea," post="convalescent plasma therapy was performed for several MERS patients,"/>
  <result pre="of convalescent plasma therapy for COVID-19 patients was conducted in" exact="China" post="[28]. To evaluate the efficacy and adverse effects of"/>
  <result pre="used in the study. However, because the COVID-19 epidemic in" exact="China" post="was contained while enrolment was in progress, the trial"/>
  <result pre="events Reference Cases Controls Cases Controls Abolghasemi et al., 2020" exact="Iran" post="Nonrandomized, controlled study 115 74 14.8% died 24.3% died"/>
  <result pre="study 2 100% improved None [23] Duan et al., 2020" exact="China" post="Nonrandomized, non-controlled study 10 100% improved within 3 days"/>
  <result pre="1 evanescent facial red spot [20] Li et al., 2020" exact="China" post="Randomized, controlled study 53 51 51.9% improved within 28"/>
  <result pre="events within hours after transfusion [28] Perotti et al., 2020" exact="Italy" post="Nonrandomized, non-controlled study 46 6.5% died within 7 days"/>
  <result pre="improved within 14 days None [25] Shen et al., 2020" exact="China" post="Nonrandomized, non-controlled study 5 100% improved None [21] Zeng"/>
  <result pre="study 5 100% improved None [21] Zeng et al., 2020" exact="China" post="Nonrandomized, non-controlled study 6 15 83% died 93% died"/>
  <result pre="83% died 93% died None [24] Zhang et al., 2020" exact="China" post="Nonrandomized, non-controlled study 4 100% improved None [22] COVID-19,"/>
  <result pre="in reported cases and clinical trials on coronaviruses [72021222328]. A" exact="United States" post="(US) study of 5,000 hospitalized adults with severe or"/>
  <result pre="conducted in patients with severe or life-threatening disease. According to" exact="the US" post="Food and Drug Administration (FDA) guidelines, investigators in the"/>
  <result pre="the US Food and Drug Administration (FDA) guidelines, investigators in" exact="the US" post="wishing to study the use of convalescent plasma in"/>
  <result pre="if available (when measurement of neutralizing antibody titers is available," exact="the US" post="FDA recommends neutralizing antibody titers of at least 1:160."/>
  <result pre="(WHO)Coronavirus disease (COVID-19) pandemicAccessed 3 August 2020Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 2GuanWJNiZYHuYLiangWHOuCQHeJXLiuLShanHLeiCLHuiDSCDuBLiLJZengGYuenKYChenRCTangCLWangTChenPYXiangJLiSYWangJLLiangZJPengYXWeiLLiuYHuYHPengPWangJMLiuJYChenZLiGZhengZJQiuSQLuoJYeCJZhuSYZhongNScollab:" exact="China" post="Medical Treatment Expert Group for Covid-19Clinical characteristics of coronavirus"/>
 </snippets>
</snippetsTree>
